Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07533955 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis | PHASE1 | RECRUITING | 36 | — | — | May 19, 2026 | Oct 1, 2028 | Jun 1, 2026 | 3 | Moldova, Ukraine |
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| JADE201 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE201 |
| Placebo | EXPERIMENTAL | Subcutaneous (SC) injection of Placebo |
| Name | Type | Description |
|---|---|---|
| JADE201 | DRUG | JADE201 is supplied as sterile solution to be administered by SC injection. |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection. |
Inclusion Criteria: 1. Male and female participants 18-70 years of age, inclusive. 2. A body weight between 50-100 kg and a body mass index (BMI) between 18-32 kg/m2 (all inclusive) at screening. 3. Confirmed diagnosis of RA according to 2010 ACR/EULAR criteria 4. Willing and able to comply with th...